T lymphopenia in multiple sclerosis patients treated with ofatumumab: Even with consideration for CD3 + CD20+ cells
{{output}}
Background: B cell depleting therapy has become a cornerstone in disease-modifying treatments for relapsing-remitting multiple sclerosis (RRMS). Given that the maximum blood concentration of ofatumumab (OFA) is two orders of magn... ...
